Patents Issued in May 20, 2021
  • Publication number: 20210145749
    Abstract: Present invention relates to a novel composition administering pharma agents using a bi-phasic recruiting moiety.
    Type: Application
    Filed: April 12, 2019
    Publication date: May 20, 2021
    Inventors: Magnus TÄGIL, Deepak Bushan RAINA, Lars Åke Alvar LIDGREN
  • Publication number: 20210145750
    Abstract: According to the present invention, there is provided a complex in which a carrier and a physiologically active substance are integrated, the complex being conveniently obtainable, having excellent efficiency for the integration of a physiologically active substance, and having a satisfactory membrane disruptive function promoting effect. The complex according to the present invention is formed by supporting a physiologically active substance on an aggregate of a pH sensitive carrier, wherein the aggregate is formed by aggregating under acidic conditions.
    Type: Application
    Filed: May 9, 2018
    Publication date: May 20, 2021
    Applicant: TERUMO KABUSHIKI KAISHA
    Inventor: Naoki SAKAGUCHI
  • Publication number: 20210145751
    Abstract: The disclosure concerns methods for executing PBV protocols to preserve biopharmaceuticals using a conventional lyophilizer. Also described are steps for maintaining isolation of a biopharmaceuticals for achieving aseptic drying using the conventional lyophilizer. As a collateral benefit, the invention provides good manufacturing practice (GMP) compliant methods for achieving aseptic drying of biopharmaceutical compositions using a conventional lyophilizer disposed outside of a clean-room area. Finally, methods and formulations str disclosed for preserving biopharmaceuticals suitable for mucosal or transdermal delivery to a patient.
    Type: Application
    Filed: July 11, 2018
    Publication date: May 20, 2021
    Applicant: Universal Stabilization Technologies, Inc.
    Inventor: Victor BRONSHTEIN
  • Publication number: 20210145752
    Abstract: A composition including an amphiphilic compound capable of self-assembling into liquid crystalline particles and a statin for systemic administration via oral mucosa. A method of lowering blood cholesterol levels in a subject comprising administering the self-assembling liquid crystalline particles and statin via oral mucosa. Preferred dosage forms result in prolonged release of the statin.
    Type: Application
    Filed: April 20, 2018
    Publication date: May 20, 2021
    Inventors: Gregory Yu Foo SZTO, Tomer MADMON, David KANNAR
  • Publication number: 20210145753
    Abstract: The solid preparation which improved the dissolution profile and the stability of the 6,7-unsaturation-7-carbamoyl morphinan derivative is provided. When 6,7-unsaturation-7-carbamoyl morphinan derivative, croscarmellose sodium and ferric oxide were contained, not titanium oxide in the solid preparations and the coating solid preparations, a dissolution rate after 15 minutes of the dissolution test is more than 85%, and stability, particularly, light stability can be improve.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 20, 2021
    Applicant: Shionogi & Co., Ltd.
    Inventors: Akira MASHIMO, Shunji ICHIO, Yoshinori TAMURA, Kouichi NOGUCHI
  • Publication number: 20210145754
    Abstract: An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.
    Type: Application
    Filed: November 23, 2018
    Publication date: May 20, 2021
    Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
    Inventors: Li DING, Jun DAI, Chunrong FENG, Changliang DAI
  • Publication number: 20210145755
    Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Inventors: Sami Karaborni, Sarina Grace Harris Ma, Chen Mao, Ching Wah Chong, Peter Robert Prinz Freed, Mesut Ciper, Stefanie Krenzlin, David Wustrow, Peter Virsik
  • Publication number: 20210145756
    Abstract: Pharmaceutical compositions and methods are provided to treat headache, headache-associated symptoms, photophobia, or adverse effects associated with the headache. Also provided herein are small smooth particulates comprising a 5HT1B/1D receptor agonist. Compositions for oral administration are described herein wherein the compositions comprise a combination of active agents, such as a 5HT1B/1D receptor agonist and one or more antiemetics.
    Type: Application
    Filed: August 13, 2020
    Publication date: May 20, 2021
    Inventors: Paul Bosse, John AMELING, William KOZAREK, Bernard SCHACHTEL, John HIGGINS
  • Publication number: 20210145757
    Abstract: Disclosed are compositions and methods for pluripotent stem cell culture. Compositions include mineral coated microparticles having a core and a mineral coating, wherein the mineral coating includes fibroblast growth factor. Also disclosed are methods for pluripotent stem cell culture methods using mineral coated microparticles including fibroblast growth factor.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 20, 2021
    Inventors: William L. Murphy, Andrew Khalil, Angela Xie, Hunter Johnson
  • Publication number: 20210145758
    Abstract: The invention provides compositions and methods that comprise encapsulated silver diamine fluoride or other antimicrobial materials for use in treatment of dental caries, for example.
    Type: Application
    Filed: December 1, 2020
    Publication date: May 20, 2021
    Applicant: Healthy Advances, Inc.
    Inventor: Jong Seto
  • Publication number: 20210145759
    Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.
    Type: Application
    Filed: March 27, 2019
    Publication date: May 20, 2021
    Inventors: Lauren Emily Barney, Michael Beauregard, Guillaume Carmona, Francisco Caballero Gonzalez, Richard Heidebrecht, Erika Ellen Johnston, Robert James Miller, Matthias Alexander Oberli, Owen O'Connor, David Peritt, Jared A. Sewell, Devyn McKinley Smith, Omid Veiseh, Paul Kevin Wotton
  • Publication number: 20210145760
    Abstract: The present invention relates to a transdermal therapeutic system (TTS) for the transdermal administration of scopolamine comprising a scopolamine-containing layer structure, said scopolamine-containing layer structure comprising: A) a backing layer; and B) a scopolamine-containing layer; wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.
    Type: Application
    Filed: June 25, 2018
    Publication date: May 20, 2021
    Inventors: Sandra WIEDERSBERG, Gerd HOFFMANN
  • Publication number: 20210145761
    Abstract: The present invention relates to a transdermal delivery system (TDS) comprising at least one dopamine agonist, wherein the at least one dopamine agonist is present in a matrix containing at least one polymer from the class of polybutylene. The present invention also relates to a method for producing the TDS according to the invention and to the use of the TDS according to the invention.
    Type: Application
    Filed: October 19, 2018
    Publication date: May 20, 2021
    Applicant: AMW GMBH
    Inventors: Stefanie RODLER, Sonja SEITZ
  • Publication number: 20210145762
    Abstract: Fullerene compounds and formulations are taught as useful in reducing oxidative stress in an organism because of their antioxidant properties and REDOX balance (homeostasis) properties.
    Type: Application
    Filed: November 15, 2019
    Publication date: May 20, 2021
    Applicant: Redox Balance LLC
    Inventor: Stephen R. Wilson
  • Publication number: 20210145763
    Abstract: The present invention relates to methods of treating or preventing AMD in a subject, the method comprising administering to the subject a therapeutically effective amount of hemp, hemp oil or pharmaceutically effective extract thereof to thereby treat or prevent the AMD. The invention also relates to pharmaceutical composition comprising a therapeutically effective amount of hemp, hemp oil; or a pharmaceutically effective extract thereof and a pharmaceutically acceptable carrier, diluent or excipient when used to treat AMD, and to uses of a pharmaceutical composition comprising hemp, hemp oil, or a pharmaceutically effective extract thereof for the manufacture of a medicament for the treatment of AMD.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventor: Philip Leslie Penfold
  • Publication number: 20210145764
    Abstract: Described herein are compositions and methods for the prevention and/or treatment of at least one condition or disorder of a) skin and accessory structures of the skin, b) musculoskeletal system, c) cardiovascular system, d) inflammatory system, e) neurological system, f) cancer, and g) endocrine/metabolic system, and/or for improving the health status of a subject. The composition includes one or more polyphenolic compound, its isomer or analog; and one or more other active ingredient selected from the group consisting of collagen, vitamin C, vitamin E, zinc, grape seed extract, niacinamide, hydroxy acids, hyaluronic acid, and coenzyme Q10. The composition may also or alternatively include cannabidiol (CBD).
    Type: Application
    Filed: November 12, 2020
    Publication date: May 20, 2021
    Applicant: BRIGHAM YOUNG UNIVERSITY
    Inventor: Edwin Douglas LEPHART
  • Publication number: 20210145765
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Application
    Filed: January 12, 2021
    Publication date: May 20, 2021
    Inventors: Geoffrey GUY, Stephen WRIGHT, Elizabeth THIELE
  • Publication number: 20210145766
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 20, 2021
    Applicant: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'MAHONY, Sharon HAMM, John DEVANE, Imran AHMED, David PENAKE
  • Publication number: 20210145767
    Abstract: Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.
    Type: Application
    Filed: January 28, 2021
    Publication date: May 20, 2021
    Applicant: SAOL INTERNATIONAL DEVELOPMENT LTD.
    Inventors: Leonard O'MAHONY, Sharon HAMM, John DEVANE, Imran AHMED, David PENAKE
  • Publication number: 20210145768
    Abstract: This disclosure provides agents that are useful for modulating an immune response in subject and for treating diseases, such as autoimmune diseases, cardiovascular diseases, infectious diseases, and cancer. These agents may comprise an olfactory receptor (OLFR), an OLFR ligand, or a protein involved in the trafficking of an OLFR to the plasma membrane of a cell. Alternatively, the agents may modulate the expression or activity of an OLFR, OLFR ligand, or protein involved in the trafficking of the OLFR to the plasma membrane of a cell.
    Type: Application
    Filed: April 15, 2019
    Publication date: May 20, 2021
    Applicant: La Jolla Institute for Allergy and Immunology
    Inventors: Klaus LEY, Marco ORECCHIONI
  • Publication number: 20210145769
    Abstract: The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.
    Type: Application
    Filed: September 17, 2020
    Publication date: May 20, 2021
    Inventors: Guy M. MILLER, Carlo DIONISI-VICI, Enrico BERTINI, Diego MARTINELLI
  • Publication number: 20210145770
    Abstract: This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 20, 2021
    Inventor: Herriot Tabuteau
  • Publication number: 20210145771
    Abstract: The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein X, a, b, C, D, L2, L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting the ATF4 pathway and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
    Type: Application
    Filed: July 2, 2018
    Publication date: May 20, 2021
    Inventors: Mui CHEUNG, Michael P. DEMARTINO, Biswajit KALITA
  • Publication number: 20210145772
    Abstract: The invention provides methods for treating acral lick granuloma in a canine using a capsaicinoid, such as capsaicin. The invention also provides methods for deactivating a nerve fiber selected from the group consisting of a C-fiber and an A-delta fiber, each being located in or proximal to an acral lick granuloma in a canine, using a capsaicinoid, such as capsaicin.
    Type: Application
    Filed: July 24, 2020
    Publication date: May 20, 2021
    Inventors: James N. Campbell, Peter D. Hanson
  • Publication number: 20210145773
    Abstract: The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 20, 2021
    Inventor: Jean-Claude TARDIF
  • Publication number: 20210145774
    Abstract: Treatment of alcoholic liver disease with seladelpar or a salt thereof.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 20, 2021
    Applicant: CymaBay Therapeutics, Inc.
    Inventor: Edward E. Cable
  • Publication number: 20210145775
    Abstract: Treatment of intestinal barrier dysfunction and associated diseases other than alcoholic liver disease or NAFLD/NASH with seladelpar or a salt thereof.
    Type: Application
    Filed: November 12, 2020
    Publication date: May 20, 2021
    Applicant: CymaBay Therapeutics, Inc.
    Inventor: Edward E. Cable
  • Publication number: 20210145776
    Abstract: Methods for the treatment of leptomeningeal disease in a pediatric patient. The leptomeningeal disease may be leptomeningeal, disseminated, and/or multicentric disease (LDM) and may be associated with one or more primary CNS tumors or one or more low-grade gliomas (LGGs). The method includes administering to a patient a plurality of extraneous antineoplastons.
    Type: Application
    Filed: June 11, 2018
    Publication date: May 20, 2021
    Inventor: Stanislaw R. Burzynski
  • Publication number: 20210145777
    Abstract: The present invention provides methods, compositions, devices, and kits for treating cystinuria or related disorders, in which tiopronin is administered to a patient according to a modified-release strategy that releases tiopronin in critically-spaced, repeated pulses over time, to provide lower peak plasma levels but consistently higher urine levels of the drug for binding cystine. In particular, use of the present modified-release formulations and systems reduce side effects of tiopronin, thereby increasing patient compliance and quality of life, as well as achieving efficacy with less frequent administrations and/or lower total dosages.
    Type: Application
    Filed: June 18, 2018
    Publication date: May 20, 2021
    Inventors: Patrick REICHENBERGER, Artem ZYKOVICH
  • Publication number: 20210145778
    Abstract: The present invention relates to a stable non-aqueous, ready to dilute liquid pharmaceutical composition comprising (i) melphalan or a pharmaceutically acceptable salt thereof and (ii) polyoxyethylene sorbitan fatty acid esters; wherein the weight ratio of melphalan to polyoxyethylene sorbitan fatty acid esters is from about 1:0.75 to about 1:20; wherein, composition comprising melphalan, at a concentration of about 50 mg/ml to about 150 mg/ml; wherein, when the composition is diluted to produce melphalan at a concentration of about 0.1 to about 3 mg/ml, is physically and chemically stable up to about 4 hours.
    Type: Application
    Filed: December 27, 2018
    Publication date: May 20, 2021
    Applicants: Orbicular Pharmaceutical Technologies Pvt. Ltd., Orbicular Pharmaceutical Technologies Pvt. Ltd.
    Inventors: Hiren Patel, Bhaveshkumar Vallabhbhai Patel, Raghu Kannekanti, Babuji Kantu, Mahesh Sanka
  • Publication number: 20210145779
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Application
    Filed: November 23, 2020
    Publication date: May 20, 2021
    Inventors: Barbara SLUSHER, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrej Jancarik, Robert Leone, Judson Englert
  • Publication number: 20210145780
    Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.
    Type: Application
    Filed: September 22, 2020
    Publication date: May 20, 2021
    Inventor: Jeffrey GREEN
  • Publication number: 20210145781
    Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.
    Type: Application
    Filed: September 22, 2020
    Publication date: May 20, 2021
    Inventor: Jeffrey GREEN
  • Publication number: 20210145782
    Abstract: A composition comprising medium-chain triglycerides (MCTs) wherein the composition comprises (i) a MCT comprising three fatty acid moieties each with 8 carbon atoms (MCT-C8) and (ii) a MCT comprising three fatty acid moieties each with 10 carbon atoms (MCT-C10); wherein the ratio of MCT-C8 to MCT-C10 is from 10:90 to 90:10 (mol/mol) and wherein the combined amount of MCT-C8 and MCT-C10 make up at least 50 mol % of the MCTs in the composition.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 20, 2021
    Inventors: Bernard Cuenoud, Mojan Masoodi
  • Publication number: 20210145783
    Abstract: It has been found that the prodrug 1-(butyryloxy)ethyl-5-amino-4-oxopentanoate (AN-233), an oral active conjugate of BA (histone deacetylase inhibitor) and ALA (heme precursor), is useful for the treatment of hemoglobinopathies including but not limited to sickle cell disease and thalassemias. In one embodiment, AN-233 activates ?-globin transcription, induces HbF expression, produces an anti-sickling effect, or combinations thereof when administered to a subject in need thereof.
    Type: Application
    Filed: November 16, 2020
    Publication date: May 20, 2021
    Inventors: Betty S. PACE, Abraham Nudelman, Zvi MALIK, Ada REPHAELI
  • Publication number: 20210145784
    Abstract: A method for treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids that ameliorate the symptoms of these diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: May 20, 2021
    Inventor: Charles R. ROE
  • Publication number: 20210145785
    Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a D-cysteine alkyl ester, adduct thereof, or pharmaceutically acceptable salt, tautomer, or solvate thereof.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 20, 2021
    Inventors: Benjamin Gaston, Stephen Lewis
  • Publication number: 20210145786
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: October 22, 2020
    Publication date: May 20, 2021
    Inventor: Joseph S. Zakrzewski
  • Publication number: 20210145787
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Application
    Filed: November 23, 2020
    Publication date: May 20, 2021
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Publication number: 20210145788
    Abstract: The invention relates to the treatment of ascites, and especially refractory ascites, with an orally bioavailable prodrug of dopamine. A preferred prodrug of dopamine is docarpamine. In one embodiment treated patients are, prior to treatment, on doses of furosemide >80 mg/day and/or spironolactone >100 mg/day or equivalent doses of an alternative loop-acting and/or distal-acting diuretic. The ascites treated by the invention are typically caused by liver cirrhosis due to alcohol or non-alcoholic fatty liver disease and generally not due to viral hepatitis or primary biliary cholangitis. Preferred dosing is greater that 2250 mg per day, with more preferred doses exceeding 3500 mg per day.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 20, 2021
    Inventors: Thomas W MacAllister, Sven M. Jacobson
  • Publication number: 20210145789
    Abstract: The present invention relates generally to intranasal pharmaceutical compositions. In particular, the present invention is directed to sustained, enhanced delivery of pharmaceutical agents across the nasal mucosa for systemic drug delivery.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Inventor: Timothy Matthias Morgan
  • Publication number: 20210145790
    Abstract: A regimen is described for providing early onset of action in the therapeutic treatment of rosacea including topically applying a pharmaceutical composition to the skin of a subject in need of said treatment. The pharmaceutical composition includes about 1% to about 10% benzoyl peroxide as the only active ingredient, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition is applied once daily for a period of at least about 2, 4, 8 or 12 weeks. Based on early onset of action, a primary measure of success is at least about 9%, primary measure of success being defined as a 2-grade improvement in IGA of clear or almost clear; and a secondary measure of success is at least about 40%, secondary measure of success being defined as mean inflammatory lesion count percent reduction from baseline, after at least about 2 weeks of treatment.
    Type: Application
    Filed: January 25, 2021
    Publication date: May 20, 2021
    Inventors: Ofer TOLEDANO, Ofra LEVY-HACHAM, Ori NOV, Vered RAM
  • Publication number: 20210145791
    Abstract: The invention relates to a new method for preparing a complex of forskolin and cyclodextrin and inclusion complexes of forskolin and ?-cyclodextrins having a weight ratio of 1:0.2 to 1:4 (w/w). Pharmaceutical compositions comprising said complex and their use are also provided.
    Type: Application
    Filed: January 9, 2018
    Publication date: May 20, 2021
    Applicant: SciPharm S.à.r.l
    Inventor: Andreas KUBIN
  • Publication number: 20210145792
    Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
    Type: Application
    Filed: November 19, 2019
    Publication date: May 20, 2021
    Applicant: Provectus Pharmatech, Inc.
    Inventor: Eric A. Wachter
  • Publication number: 20210145793
    Abstract: A liquid cannabinoid composition is disclosed, said liquid cannabinoid composition comprising a carrier liquid, and a tetrahydrocannabinolic compound and/or a cannabidiolic compound, wherein at least 95 percent by weight of said tetrahydrocannabinolic compound and/or cannabidiolic compound is present in carboxylated inactive form.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 20, 2021
    Inventors: Søren Christian Schou, Heidi Ziegler Bruun
  • Publication number: 20210145794
    Abstract: The disclosure concerns the use of LIK066 in the treatment, prevention or delay of non-alcoholic steatohepatitis.
    Type: Application
    Filed: June 20, 2018
    Publication date: May 20, 2021
    Inventors: Lloyd Klickstein, C. Daniel Meyers, Chinweike Ukomadu
  • Publication number: 20210145795
    Abstract: The invention provides an agent for the treatment or prevention of viral infection in a subject. The agent is preferably a compound of Formula (I) wherein R1-R11, X, Y and Q are as defined herein. Also provided are pharmaceutical compositions and combinations comprising such agents. An in vitro method of evaluating the antiviral activity or potential antiviral activity of a compound against a virus is also provided.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventors: Kin-Chow CHANG, Leah Victoria GOULDING
  • Publication number: 20210145796
    Abstract: Compositions and methods of enhancing the potency and efficacy of adoptive cell therapy using integrin-ligand stabilizers, wherein the integrin is selected from the group consisting of ?4?1, ?5?1, ?4?7, ?v?3 and ?L?2, and contacting the effector cells ex vivo with agonists or stabilizers having the general Formula (I); methods of treating integrin-expressing cells with such stabilizers to enhance tumor infiltration; and therapeutic methods comprising administering stabilizer or agonist-treated cells to a mammal requiring treatment of solid tumors, hematologic cancers.
    Type: Application
    Filed: October 26, 2020
    Publication date: May 20, 2021
    Inventor: Upendra K. Marathi
  • Publication number: 20210145797
    Abstract: The present disclosure provides compositions and methods for promoting stem cell and/or progenitor cell proliferation and/or differentiation. The provided compositions useful in treating and/or preventing wounds or burns, treating and/or preventing skin conditions (e.g., atopic dermatitis, psoriasis, bed sores, conditions related to the aging of skin, pruritus, eczema or herpes simplex), or treating and/or preventing fibrosis, in a subject in need thereof. The present disclosure also provides methods for treating and/or preventing wounds or burns, treating and/or preventing skin conditions, or treating and/or preventing fibrosis in a subject in need of such treatment by administering a composition.
    Type: Application
    Filed: April 4, 2019
    Publication date: May 20, 2021
    Inventor: Sadasivan VIDYASAGAR
  • Publication number: 20210145798
    Abstract: A method for treating amyotrophic lateral sclerosis includes administering an effective amount of 3-methyl-1-phenyl-2-pyrazolin-5-one or a physiologically acceptable salt thereof to a patient who is in need thereof and meets two or more features selected from a group of identified features.
    Type: Application
    Filed: October 4, 2018
    Publication date: May 20, 2021
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Charlotte MERRILL, Wendy AGNESE, Nazem ATASSI, Tara GRABOWSKY, Takeshi SAKATA